KHẢO SÁT KẾT QUẢ KIỂM SOÁT MỤC TIÊU NỒNG ĐỘ LDL-C HUYẾT THANH Ở BỆNH NHÂN BỆNH ĐỘNG MẠCH VÀNH MẠN ĐÃ ĐIỀU TRỊ ROSUVASTATIN 10MG TẠI BỆNH VIỆN TIM MẠCH THÀNH PHỐ CẦN THƠ NĂM 2021-2022

Abstract

Background: Dyslipidemia is a common cardiovascular risk factor in clinical practice, increasing dangerous cardiovascular complications. Rosuvastatin is a statin commonly recommended for use in many countries worldwide. Therefore, it is necessary to conduct a study to evaluate its effectiveness and safety in patients with chronic coronary artery disease (CAD). Objectives: To determine the rate of serum LDL-c goal failure and investigate the factors associated with the serum LDL-c target failure rate in patients with chronic coronary artery disease treated with Rosuvastatin 10mg ≥4 weeks. Materials and methods: A cross-sectional study on 206 patients diagnosed with CAD treated with Rosuvastatin 10mg ≥4 weeks at Can Tho Cardiovascular Hospital from April 2021 to March 2022. Results: The percentage of patients who did not reach the target LDL-c concentration < 1.8mmol/l accounted for 68.4%. The proportion of patients with LDL-c disorder according to NCEP-ATP III 2004: the optimal level is 70.87%, the near-normal level is 15.53%, the borderline high is 7.77%, the high level is 4.85%, the very high increase is 0.97%. Cardiovascular risk factors: the prevalence of obesity and overweight is 62.6%, smoking is 24.3%, physical inactivity is 56.3%, hypertension is 58.7%, and diabetes is 41.3%. Female gender, BMI, overweight and obesity, and physical inactivity are associated with the rate of not reaching the target LDL-c concentration <1.8mmol/l (p<0.05). Conclusion: The proportion of patients who did not match the target of LDL-c concentration < 1.8mmol/l accounted for 68.4%. Female gender, BMI, overweight and obesity, and physical inactivity were associated with the rate of not reaching the target LDL-c concentration <1.8 mmol/l.